Osteopontin plasma level does not detect prostate cancer in patients referred for diagnostic prostate biopsy

International Journal of Biological Markers

Volumn 25, Issue 4, 2010, Pages 200-206

  Puzone, Roberto ^a   Paleari, Laura ^a   Montefiore, Franco ^b   Ruggiero, Luca ^b   Puntoni, Matteo ^c   Maffezzini, Massimo ^c   Bobbio, Barbara ^a   Marroni, Paola ^a   Libener, Roberta ^d   Betta, Pier Giacomo ^d  

^a UNIVERSITY OF GENOA   (Italy)

^b SGiacomo Hospital ASL Alessandria   (Italy)

^c GALLIERA HOSPITAL   (Italy)

^d C Arrigo Children's Hospital   (Italy)

Author keywords

Circulating tumor markers; Osteopontin; Prostate cancer; PSA

Indexed keywords

BIOLOGICAL MARKER; OSTEOPONTIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; BIOPSY; CASE-CONTROL STUDIES; HUMANS; MALE; MIDDLE AGED; OSTEOPONTIN; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650846774     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2010.6116     Document Type: Article

References (27)

1. Linton KD, Hamdy FC. Early diagnosis and surgical management of prostate cancer. Cancer Treat Rev 2003; 29: 151-60.
2. Shteynshlyuger A, Andriole GL. Prostate cancer: to screen or not to screen? Urol Clin North Am 2010; 37: 1-9.
3. Parekh DJ, Ankerst DP, Baillargeon J, et al. Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 1966-72.
4. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. CMAJ. 2007; 176: 1853-8.
5. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46.
6. Wolf A, Wender R, Etzioni R, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010; 60: 70-98.
7. Sodek J, Ganss B, Mc Kee MD. Osteopontin. Crit Rev Oral Biol Med 2000; 11: 279-303.
8. Reinhold FP, Hultenby H, Oldberg A, et al. Osteopontin - a possible anchor of osteoclast to bone. Proc Natl Acad Sci USA 1990; 87: 4473-5.
9. Denhardt DT, Noda M, O'Regan AW, et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodelling, and cell survival. J Clin Invest 2001; 107: 1055-61.
10. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
11. Shijubo N, Uede T, Kon S, et al. Vascular endothelial growth factor and osteopontin in tumour biology. Crit Rev Oncol 2000; 11: 135-46.
12. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 2001; 6: 419-29.
13. Thalmann GN, Sikes RA, Devoll RE, et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 1999; 5: 2271-7.
14. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profile. J Natl Cancer Inst 2002; 94: 513-21.
15. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 1671-9.
16. Ue T, Yokozaki H, Kitadai Y, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998; 79: 127-32.
17. Chambers AF, Wilson SM, Kerkvliet N, et al. Osteopontin expression in lung cancers. Lung Cancer 1996; 15: 311-23.
18. Angelucci A, Festuccia C, Gravina GL, et al. Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. Prostate 2004; 59: 157-66.
19. Cooper CR, Chay CH, Pienta KJ. The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia 2002; 4: 191-4.
20. Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 2007; 67: 330-40.
21. Castellano G, Malaponte G, Mazzarino MC, et al. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res 2008; 14: 7470-80.
22. Jain A, McKnight DA, Fisher LW, et al. Small integrin-binding proteins as serum markers for prostate cancer detection. Clin Cancer Res 2009;15: 5199-207.
23. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU Int 2002; 89: 538-42.
24. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumors. Pathology and genetics of tumours of the urinary system and male genital Organs. Lyon: IARC Press, 2004.
25. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst 2006; 98: 529-34.
26. Forootan SS, Foster CS, Aachi VR, et al. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 2006; 118: 2255-61.
27. Caruso DJ, Carmack AJK, Lokeshwar VB, et al. Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clin Cancer Res 2008; 14: 4111-8.